<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005616</url>
  </required_header>
  <id_info>
    <org_study_id>99-035A</org_study_id>
    <secondary_id>CDR0000067753</secondary_id>
    <secondary_id>BOEH-1152.5</secondary_id>
    <secondary_id>LUDWIG-LUD98-006</secondary_id>
    <secondary_id>NCI-G00-1756</secondary_id>
    <nct_id>NCT00005616</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer</brief_title>
  <official_title>A Phase I Single Dose-Escalation Study of BIBH-1 in Patients With Colorectal Cancer Scheduled for Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating&#xD;
      patients who have colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine any toxicity associated with increasing single doses of monoclonal&#xD;
      antibody F19 (BIBH-1) administered by intravenous infusion in patients with colorectal cancer&#xD;
      scheduled for surgical resection. II. Compare the pharmacokinetics, biodistribution, and&#xD;
      imaging characteristics of increasing intravenous doses of iodine I 131 BIBH-1 in this&#xD;
      patient population. III. Compare the BIBH-1 related human antihuman antibody (HAHA) serum&#xD;
      concentration with immunologic related clinical effects in these patients. IV. Compare the&#xD;
      uptake of iodine I 131 BIBH-1 in tumor to the uptake of normal tissue when administered to&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study. Patients receive monoclonal antibody F19 (BIBH-1)&#xD;
      combined with iodine I 131 IV over 60 minutes. Patients undergo surgical resection&#xD;
      approximately 7 days after BIBH-1 infusion. Cohorts of 3-6 patients receive escalating doses&#xD;
      of BIBH-1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the&#xD;
      dose preceding that at which 2 of 6 patients experience dose limiting toxicities. Patients&#xD;
      are followed once during days 5-14 and then at day 30 after surgery.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study within 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1999</start_date>
  <completion_date type="Actual">August 2000</completion_date>
  <primary_completion_date type="Actual">August 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radionuclide imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iodine I 131 monoclonal antibody F19</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed primary colorectal cancer Candidate for a&#xD;
        clinically indicated laparotomy for primary tumor resection, resection of hepatic&#xD;
        metastases, or placement of an intrahepatic arterial catheter No active CNS metastases&#xD;
        defined by new or enlarging lesions on CT scan or within 3 months of treatment (i.e.,&#xD;
        surgery or radiotherapy) for brain metastases No prior participation in this study&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life&#xD;
        expectancy: At least 3 months Hematopoietic: Granulocyte count at least 2,500/mm3&#xD;
        Lymphocyte count greater than 700/mm3 Platelet count at least 100,000/mm3 Hepatic: ALT/AST&#xD;
        no greater than 3 times upper limit of normal Bilirubin less than 2 mg/dL Renal: Creatinine&#xD;
        no greater than 2.0 mg/dL Other: No pregnant or nursing Negative pregnancy test Fertile&#xD;
        patients must use effective contraception No incomplete healing at an incision site as&#xD;
        evidenced by incomplete granulation, infection, or localized edema No active infections&#xD;
        requiring antibiotics No bleeding disorders No other serious illness that may potentially&#xD;
        interfere with obtaining accurate study results No autoimmune disease No hypertrophic skin&#xD;
        conditions&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy No&#xD;
        prior murine, chimeric, or humanized antibody and/or antibody fragment Chemotherapy: At&#xD;
        least 4 weeks since prior chemotherapy Endocrine therapy: No concurrent systemic&#xD;
        corticosteroids except for acute management of allergic type events Radiotherapy: See&#xD;
        Disease Characteristics Surgery: See Disease Characteristics Recovered from prior surgery&#xD;
        Other: At least 4 weeks since other prior investigational agents No concurrent&#xD;
        immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sydney Welt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>June 17, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2004</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage I colon cancer</keyword>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

